Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
N/A
2(50.0%)
4Total
Phase 2(2)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05892237Phase 2Recruiting

CIETAI and Sequential Radiotherapy in Squamous Lung Cancer

Role: lead

NCT04471480Not ApplicableUnknown

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer

Role: lead

NCT04063449Not ApplicableUnknown

Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC

Role: lead

NCT04060472Phase 2Unknown

Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors

Role: lead

All 4 trials loaded